Search results for "blood eosinophil"

showing 8 items of 8 documents

Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy.

2009

Background: To date, no predictive tests for the clinical response to allergen-specific immunotherapy (ASI) are available. Therefore an in vivo or in vitro test would be of great value. Objective: We sought to evaluate pretreatment parameters used in diagnosing allergic rhinitis and determining serum specific IgE (s-IgE) levels, serum total IgE (t-IgE) levels, and blood eosinophil counts and to identify whether can be used to predict clinical improvement in monosensitized patients with allergic rhinitis with or without asthma treated with immunotherapy. Methods:We analyzed 279 patients who had undergone 4 years of ASI administered either by means of the subcutaneous immunotherapy (76 patien…

AdultMaleAllergySettore MED/09 - Medicina InternaRhinitis Allergic PerennialAdolescentmedicine.medical_treatmentImmunologyspecific IgEImmunoglobulin Eblood eosinophil countsYoung AdultBlood serummedicineImmunology and AllergyHumansreceiver operating characteristic curveAsthmaDesensitization (medicine)Retrospective StudiesSkin Testsserum s-IgE/total IgE ratio; allergen-specific immunotherapyHouse dust miteserum s-IgE/total IgE ratiobiologyserum-specific IgE/serum total IgE ratiobusiness.industryAllergen-specific immunotherapy; blood eosinophil counts; receiver operating characteristic curve; serum-specific IgE/serum total IgE ratio; specific IgE; total IgEArea under the curveImmunotherapyAllergensImmunoglobulin EMiddle Agedmedicine.diseasebiology.organism_classificationPrognosisAllergen-specific immunotherapyBlood Cell Counttotal IgEEosinophilsTreatment OutcomeDesensitization ImmunologicSpirometryImmunologybiology.proteinFemalebusiness
researchProduct

Differences and Similarities between Allergic and Nonallergic Rhinitis in a Large Sample of Adult Patients with Rhinitis Symptoms

2010

<i>Background:</i> Allergic rhinitis (AR) and nonallergic rhinitis (NAR) may present with different clinical and laboratory characteristics. <i>Methods:</i> A total of 1,511 consecutive patients, aged 18–81 years, diagnosed with rhinitis, 56% females and 44% males, underwent complete allergic evaluation including skin prick test, blood eosinophil counts, nasal eosinophil counts, peak nasal inspiratory flow (PNIF) measurement and evaluation of nasal symptoms using a visual analog scale (VAS). <i>Results:</i> A total of 1,107 patients (73%)had AR, whereas 404 (27%) had NAR. Patients with NAR were older and predominantly female. A higher nasal eosinophils co…

AdultMaleNasal eosinophilAgingAllergyRhinitis Allergic PerennialSkin prick testPeak nasal inspiratory flowAdolescentNon allergic rhinitisVisual analogue scaleNon-allergic rhinitisImmunologyHistamine AntagonistsReceiver operating characteristicSettore MED/42 - Igiene Generale E ApplicataSeverity of Illness IndexAllergic rhinitisYoung AdultSex FactorsNonallergic rhinitisBlood eosinophilAllergic rhinitis; Non allergic rhinitis; Skin prick test; Peak nasal inspiratory flow; Blood eosinophil; Nasal eosinophil; Visual analog scale; Receiver operating characteristicHumansImmunology and AllergyMedicineAllergic rhinitis Non allergic rhinitis Skin prick test Peak nasal inspiratory flow Blood eosinophil Nasal eosinophil Visual analog scale Receiver operating characteristicVisual analog scaleYoung adultAgedRhinitisSkin TestsAged 80 and overAdult patientsbusiness.industryHeadacheGeneral MedicineMiddle AgedEosinophilConjunctivitismedicine.diseaseLarge sampleEosinophilsmedicine.anatomical_structureSettore MED/31 - OtorinolaringoiatriaImmunologyFemaleNasal Obstructionbusiness
researchProduct

Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes

2019

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaTreatment outcomeMEDLINEOmalizumabOmalizumabSettore MED/10 - Malattie Dell'Apparato RespiratorioImmunoglobulin Eeosinophil Omalizumab anti-IgE asthmaLeukocyte CountText miningForced Expiratory VolumeInternal medicineEosinophiliamedicineHumansImmunology and AllergyAnti-Asthmatic AgentsBlood eosinophilAgedRetrospective StudiesAsthmabiologybusiness.industryRetrospective cohort studyMiddle AgedasthmaPrognosismedicine.diseaseEosinophilsTreatment Outcomeinflammationbiology.proteinFemalebusinessmedicine.drug
researchProduct

Iperreattività bronchiale aspecifica in pazienti monosensibili con rinite allergica: variazioni stagionali in rapporto alle IgE sieriche totali ed ag…

2005

Introduction: The significance of the association between allergic rhinitis and abnormal airway responsiveness is unclear. For this reason, we have studied, in patients with seasonal allergic rhinitis, non specific bronchial hyperreactivity, total serum IgE and blood eosinophils, with reference to the responsible allergen, during and out of the pollen season. Materials and methods: Fourty-nine, non-smoking patients, living in Palermo, with clinical diagnosis of allergic rhinitis, skin prick tests and specific serum IgE mono-sensitive to pollen allergens, were enrolled in the study. Twenty patients suffered from seasonal rhinitis to Parietaria pollen, 15 patients to Graminacee pollen and 14 …

Blood eosinophils countNon specific bronchial hyperreactivitySeasonal allergic rhinitiTotal serum IgEPC20-FEV1
researchProduct

Dažādu astmas vērtēšanas parametru korelācija: plaušu funkcija (FEV), NO izelpas gaisā (FeNO) un eozinofīlu skaits asinīs.

2018

Mūsu pētījuma galvenais mērķis bija novērtēt korelāciju starp dažādiem astmas vērtēšanas parametriem, piemēram, forsētās izelpas tilpumu pirmās sekundes laikā (FEV1), frakcionēto slāpekļa oksīdu slāpekļa oksīdu (FeNO) un eozinofilo leikocītu skaitu venozās asinīs pacientiem ar bronhiālo astmu, lietojot inhalējamo kortikosteroīdu ārstēšanā. Pētījuma tika iekļauti 180 pacienti vecumā no 18 līdz 75 gadiem, ar astmas diagnozi un atgriezenisku obstrukciju, kuri tika ārstēti ar 2.-4. ārstēšanas soli atbilstoši Globālās astmas iniciatīvas (GINA) vadlīnijām. Pētījuma populācijā bija 108 sievietes un 72 vīrieši. No kuriem 114 bija nesmēķētāji, 30 bijušie smēķētāji un 36 smēķētāji. 108 pacienti jeb 6…

FEV1CORRELATIONFeNOBlood eosinophilsMedicīna
researchProduct

Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

2020

Background: Inflammation is a long-established hallmark of liver fibrosis and carcinogenesis. Eosinophils are emerging as crucial components of the inflammatory process influencing cancer development. The role of blood eosinophils in patients with hepatocellular carcinoma receiving systemic treatment is an unexplored field. Objective: The objective of this study was to analyse the prognostic role of the baseline eosinophil count in patients with sorafenib-treated hepatocellular carcinoma. Patients and methods: A training cohort of 92 patients with advanced- or intermediate-stage sorafenib-treated hepatocellular carcinoma and two validation cohorts of 65 and 180 patients were analysed. Overa…

OncologySorafenibCancer Researchmedicine.medical_specialtybusiness.industrynoneMEDLINEmedicine.diseaseOncologyInternal medicineHepatocellular carcinomamedicinePharmacology (medical)In patientbusinessBlood eosinophilmedicine.drug
researchProduct

Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma.

2021

Objective: This study analysed whether the persistence of both reversible airway obstruction (RAO) and elevated BE counts was associated to reduced asthma control and accelerated lung function decline in treated severe asthmatics. Methods: About 202 severe asthmatics were studied after 12–120 months of step-5 treatment associated to anti-IgE therapy. Following treatments, reversibility tests, after inhaling 400 mcg of Salbutamol, were performed. FEV1 > 12% or ≤12% changes differentiated RAO+ from RAO− subjects. Blood eosinophil (BE) counts after treatment were considered. Results: Pre-/post-treatment bronchodilator FEV1% and ACT were lower (61% [50–71], 74.4% [62.5–83.7] and 20[18–22]), …

Pulmonary and Respiratory Medicinesevere asthmamedicine.medical_specialtymedicine.drug_classSevere asthmaEosinophilSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologyPersistence (computer science)03 medical and health sciences0302 clinical medicineInternal medicineBronchodilatorallergic asthma blood eosinophil bronchodilator reversibility lung function decline severe asthma salbutamolForced Expiratory VolumemedicineSettore MED/10Immunology and AllergyHumans030212 general & internal medicineBlood eosinophilLungGenetics (clinical)Lung functionBronchodilator Agentallergic asthma; blood eosinophil; bronchodilator reversibility; lung function decline; severe asthma; salbutamol; bronchodilator agents; eosinophils; forced expiratory volume; humans; lung; airway obstruction; asthmabusiness.industrylung function declineAirway obstructionmedicine.diseaseAsthmaBronchodilator AgentsAirway ObstructionEosinophilsbronchodilator reversibility030228 respiratory systemsalbutamolSalbutamolBlood eosinophilsbusinessallergic asthmamedicine.drugHumanblood eosinophilThe clinical respiratory journalREFERENCES
researchProduct

Mepolizumab for eosinophilic chronic obstructive pulmonary disease

2017

BACKGROUNDPatients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5.METHODSWe performed two phase 3, randomized, placebo-controlled, double-blind, parallel-group trials comparing mepolizumab (100 mg in METREX, 100 or 300 mg in METREO) with placebo, given as a subcutaneous injection every 4 weeks for 52 weeks in patients with COPD who had a history of moderate or severe exacerbations while taking inhaled glucocorticoid-based triple maintenance therapy. In METREX, unselected patients in the modified intention-to-treat population with an eosinophilic phenotype were …

medicine.medical_specialtyPARALLEL-GROUPPopulationPlacebo-controlled studyPNEUMONIA RISKPlaceboPLACEBO-CONTROLLED TRIALGastroenterology03 medical and health sciencesDOUBLE-BLIND0302 clinical medicineMaintenance therapyInternal medicineEosinophilicmedicineINHALED FLUTICASONE FUROATE030212 general & internal medicineeducationCOPDeducation.field_of_studyIntention-to-treat analysisCOPD ASSESSMENT TESTSPUTUM EOSINOPHILIAbusiness.industryGeneral MedicineRANDOMIZED CONTROLLED-TRIALBLOOD EOSINOPHILSmedicine.diseaseSECONDARY ANALYSIS030228 respiratory systemImmunologybusinessMepolizumabmedicine.drug
researchProduct